Design and In Vitro Evaluation of a Biodegradable Polymer Stent for Coronary Artery Applications
DOI:
https://doi.org/10.5281/zenodo.22479905Keywords:
biodegradable polymer stent, bioresorbable vascular scaffold, poly-L-lactic acid, coronary artery disease, in vitro degradationAbstract
Background: Permanent metallic drug-eluting stents leave a durable implant after vessel healing, motivating development of biodegradable polymer coronary stents that provide temporary scaffolding before resorbing. Objective: This narrative review synthesizes published in vitro, preclinical, and clinical evidence on biodegradable polymer coronary stents. Methods: Peer-reviewed literature on poly-L-lactic acid (PLLA)-based scaffolds (Igaki-Tamai, Absorb bioresorbable vascular scaffold), alternative polymer platforms (DESolve, Fantom), and bioresorbable magnesium comparators was reviewed for materials, degradation kinetics, mechanical bench testing, and randomized trial outcomes. Findings: PLLA backbones require thicker struts than metallic alloys to match acute radial strength, and this strut-thickness penalty was associated with excess device thrombosis and target lesion failure for Absorb in randomized trials, prompting its 2017 market withdrawal, whereas long-term Igaki-Tamai follow-up and improved-technique Absorb registries showed more favorable outcomes. Conclusions: Biodegradable polymer stents remain biologically appealing, but clinical success requires thinner, mechanically optimized backbones, degradation kinetics matched to vascular healing, and disciplined implantation technique.
References
Costa MA, Simon DI (2005). Molecular basis of restenosis and drug-eluting stents. Circulation, 111(17), 2257-2273. DOI: 10.1161/01.CIR.0000163587.36485.A7.
Buccheri D, Piraino D, Andolina G, Cortese B (2016). Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. Journal of Thoracic Disease, 8(10), E1150-E1162.
Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Motohara S, Uehata H (2000). Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation, 102(4), 399-404. DOI: 10.1161/01.CIR.102.4.399.
Nishio S, Kosuga K, Igaki K, Okada M, Kyo E, Tsuji T, Takeuchi E, Inuzuka Y, Takeda S, Hata T, Takeuchi Y, Kawada Y, Harita T, Seki J, Akamatsu S, Hasegawa S, Bruining N, Brugaletta S, de Winter S, Muramatsu T, Onuma Y, Serruys PW, Ikeguchi S (2012). Long-term (>10 years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation, 125(19), 2343-2353. DOI: 10.1161/CIRCULATIONAHA.110.000901.
Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, García-García HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R (2014). Decade of histological follow-up for a fully biodegradable poly-L-lactic acid coronary stent (Igaki-Tamai stent) in humans: are bioresorbable scaffolds the answer? Circulation, 129(1), 110-115. DOI: 10.1161/CIRCULATIONAHA.113.003769.
Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, Erne P, Haude M, Heublein B, Horrigan M, Ilsley C, Böse D, Koolen J, Lüscher TF, Weissman N, Waksman R (2007). Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. The Lancet, 369(9576), 1869-1875. DOI: 10.1016/S0140-6736(07)60853-8.
Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators (2015). Everolimus-eluting bioresorbable scaffolds for coronary artery disease. New England Journal of Medicine, 373(20), 1905-1915. DOI: 10.1056/NEJMoa1509038.
Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carrié D, Piek JJ, Van Boven AJ, Dominici M, Dudek D, McClean D, Helqvist S, Haude M, Reith S, de Sousa Almeida M, Campo G, Iñiguez A, Sabaté M, Windecker S, Onuma Y (2016). Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. The Lancet, 388(10059), 2479-2491. DOI: 10.1016/S0140-6736(16)32050-5.
Ali ZA, Serruys PW, Onuma Y, Fajadet J, Sabaté M, Whitbourn R, Rapoza R, Sudhir K, Cutlip DE, Stone GW (2017). The state of the Absorb bioresorbable scaffold: consensus from an expert panel. JACC: Cardiovascular Interventions, 10(21), 2143-2159. DOI: 10.1016/j.jcin.2017.09.041.
Grabow N, Bünger CM, Schultze C, Schmohl K, Martin DP, Williams SF, Sternberg K, Schmitz KP (2022). Development of biodegradable polymeric stents for the treatment of cardiovascular diseases. Biomaterials Research, 26, article 41.
Zhang H, et al. (2024). Influence of stent structure on mechanical and degradation properties of poly (lactic acid) vascular stent. PMC12295491.
Stone GW, Kimura T, Gao R, Kereiakes DJ, Ellis SG, Onuma Y, Cheong WF, Zhang Z, Yan J, Metzger DC, Roberts DA, Wang J, Simonton CA, Serruys PW (2019). Clinical outcomes before and after complete everolimus-eluting bioresorbable scaffold resorption: five-year follow-up from the ABSORB III trial. Circulation, 140(25), 2096-2109. DOI: 10.1161/CIRCULATIONAHA.119.042584.
Wang Y, et al. (2025). Improved vascular response to a novel polymeric blend PLLA/PLGA coronary scaffold material: preclinical study. Scientific Reports, 15, article 15997.
Mattesini A, Bartolini D, Sorini Dini C, Valente S, Parodi G, Stolcova M, Meucci F, Di Mario C (2017). The DESolve novolimus bioresorbable scaffold: from bench to bedside. Journal of Thoracic Disease, 9(Suppl 9), S950-S958.
Haude M, Ince H, Abizaid A, Toelg R, Lemos PA, von Birgelen C, Christiansen EH, Wijns W, Neumann FJ, Kaiser C, Eeckhout E, Lim ST, Escaned J, Garcia-Garcia HM, Waksman R (2016). Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. European Heart Journal, 37(35), 2701-2709.
Obayi CS, Tolouei R, Paternoster C, Turgeon S, Okorie BA, Obikwelu DO, Mantovani D (2020). Are Fe-based stenting materials biocompatible? A critical review of in vitro and in vivo studies. Journal of Functional Biomaterials, 11(2), 39.
Kim J, et al. (2025). A comparative in vitro study of distinct and novel stent geometries on mechanical performances of poly-L-lactic acid cardiovascular stents. Artificial Organs. DOI: 10.1111/aor.14893.
Yamaji K, Ueki Y, Souteyrand G, Daemen J, Wiebe J, Nef H, Adriaenssens T, Loh JP, Lattuca B, Wykrzykowska JJ, Gutierrez-Chico JL, Onuma Y, Radu MD, Räber L (2017). Mechanisms of very late bioresorbable scaffold thrombosis: the INVEST registry. Journal of the American College of Cardiology, 70(19), 2330-2344. DOI: 10.1016/j.jacc.2017.09.014.
Ali ZA, Gao R, Kimura T, Onuma Y, Kereiakes DJ, Ellis SG, Chevalier B, Vu MT, Zhang Z, Simonton CA, Serruys PW, Stone GW (2018). Very late scaffold thrombosis of bioresorbable vascular scaffold: systematic review and a meta-analysis. JACC: Cardiovascular Interventions, 11(4), 385-390. Related analysis originally published in JACC: Cardiovascular Interventions (2016). DOI: 10.1016/j.jcin.2016.10.027.
Abizaid A, Carrié D, Frey N, Lutz M, Weber-Albiez C, Dudek D, Sabaté M, Wojakowski W, Verheye S, Rensing BJ, Windhövel U, Grube E (2019). Clinical and angiographic outcomes with a novel radiopaque sirolimus-eluting bioresorbable vascular scaffold: the FANTOM II study. Circulation: Cardiovascular Interventions, 12(3), e007283. DOI: 10.1161/CIRCINTERVENTIONS.118.007283.
Kereiakes DJ, Ellis SG, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Nogueira R, Cutlip DE, Zhang Z, Simonton CA, Stone GW (2017). 3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III trial. Journal of the American College of Cardiology, 70(23), 2852-2862. DOI: 10.1016/j.jacc.2017.10.010.
Wykrzykowska JJ, Kraak RP, Hofma SH, van der Schaaf RJ, Arkenbout EK, IJsselmuiden AJ, Elias J, van Dongen IM, Tijssen RYG, Koch KT, Baan J, Vis MM, de Winter RJ, Piek JJ, Tijssen JGP, Henriques JPS; AIDA Investigators (2017). Bioresorbable scaffolds versus metallic stents in routine PCI. New England Journal of Medicine, 376(24), 2319-2328. DOI: 10.1056/NEJMoa1614954.
Ali ZA, Serruys PW, Kimura T, Gao R, Ellis SG, Kereiakes DJ, Onuma Y, Simonton C, Zhang Z, Stone GW (2017). 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. The Lancet, 390(10096), 760-772. DOI: 10.1016/S0140-6736(17)31470-8.
Onuma Y, Yamaji K, Kimura T, Chevalier B, Ellis SG, Ali Z, Chen Y, Zhang Y, Su X, Kandzari D, Cannon L, Windecker S, Kereiakes DJ, Serruys PW, Stone GW (2023). 5-year outcomes after bioresorbable coronary scaffolds implanted with improved technique. Journal of the American College of Cardiology, 81(24), 2298-2309. DOI: 10.1016/j.jacc.2023.05.003.
Verheye S, Wlodarczak A, Montorsi P, Torzewski J, Bennett J, Haude M, Starmer G, Buck T, Ferdinande B, Nef H, Vermeersch P, Wiemer M, Uzun G, Ince H (2021). Twelve-month outcomes of 400 patients treated with a resorbable magnesium scaffold: insights from the BIOSOLVE-IV registry. EuroIntervention, 17(10), 823-832.
Onuma Y, Serruys PW (2018). Fully bioresorbable vascular scaffolds: lessons learned and future directions. Nature Reviews Cardiology, 15(8), 447-448. DOI: 10.1038/s41569-018-0124-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Astrid Larsen, et al.

This work is licensed under a Creative Commons Attribution 4.0 International License.